Technology for preparing anti influenza virus transfer factors

[0024] Example 1: Preparation of anti-influenza virus transfer factor

[0025] A kind of preparation technology of anti-influenza virus transfer factor of the present invention comprises the following steps:

[0026] (1) Preparation of raw materials: 10 healthy 6-month-old pigs with no medical history were selected and immunized with influenza virus vaccine subcutaneously at a dose of 1 unit / 100kg. After 15 days, they were immunized again with the same dose as above. They were slaughtered 15-20 days after the second immunization, and the spleen and thymus were taken out, stored on ice, and stored at -20°C for later use.

[0027] (2) Pretreatment: After weighing the pig spleen, wash the pig spleen with cold three-distilled water, cut off its fascia and adipose tissue with scissors, and then wash it with cold three-distilled water.

[0028] (3) Crushing: Cut the pig spleen washed above into pieces, add 2 times the volume of cold normal saline, and mash it with a high-speed tiss...

[0035] Embodiment two: the detection of the anti-influenza virus transfer factor prepared by the process of the present invention

[0036] The anti-influenza virus transfer factor (hereinafter referred to as "this product") prepared by the process described in Example 1 is detected as follows:

[0037] 1) Ultraviolet spectrophotometric measurement: This product has a high absorption peak at 250.0-252.0nm, and ABS260 / ABS280>2.0.

[0038] 2) The standard solution is light yellow and the pH value is between 6.0 and 6.5.

[0039] 3) 20% sulfosalicylic acid test: This product has no turbidity and precipitation, indicating that the protein reaction is negative, and it does not contain macromolecular proteins.

[0040] 4) Determination of peptide content: The peptide content of this product is 1.130 mg / ml as determined by the biuret method.

[0041] 5) Determination of nucleic acid content: The nucleic acid content of this product is 532.899 μg / ml as determined by the orcinol metho...

[0047] Embodiment three: the application of the anti-influenza virus transfer factor prepared by the process of the present invention

[0048] The anti-influenza virus transfer factor solution prepared in Example 1 was added 15% syrup and standard preservatives, such as 0.25% sodium benzoate, according to the requirements of oral liquid, and then divided into 10ml / bottles.

[0049] In addition to the above syrup dosage form, the anti-influenza virus transfer factor of the present invention can also be made into other oral liquids.

[0050] In addition, the powder of the anti-influenza virus transfer factor can be further obtained through a conventional freeze-drying process, and combined with conventional auxiliary materials, it can be made into dosage forms such as capsules and tablets.